Figure 5. In vivo Barasertib treatment prevents from TGFα induced lung fibrosis.

• A
  Schematic illustration of barasertib preventive treatment protocol. Control and TGFα mice were treated with either vehicle or barasertib (40 mg/kg; twice a day) for 4 weeks, while they were fed with Dox‐containing food.
• B
  Representative images of Masson's trichrome‐stained lung sections from the vehicle‐ and barasertib‐treated mice. Images were obtained at 10× magnification. Scale bar: 200 μm.
• C
  Quantification of right lung weight of mice treated with vehicle or barasertib. ***P < 0.0005, ****P < 0.00005, 1‐way ANOVA (n = 8–10 mice/group).
• D
  Quantification of total lung hydroxyproline levels in mice treated with vehicle or barasertib. *P < 0.05, ***P < 0.0005, 1‐way ANOVA (n = 8–10 mice/group).
• E
  Quantification of Col1α, Col5α, and Fn1 gene transcripts in total lung of mice treated with vehicle or barasertib. ***P < 0.0005, ****P < 0.00005, 1‐way ANOVA (n = 8 mice/group).

Data information: All data were presented as mean ± SEM. P values were shown in Appendix Table S6.